ChromaDex Corporation
CDXCNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CDXC. That does not mean none is planned.
Get an email about CDXC's next catalysts
Track ChromaDex (CDXC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
CHR-2797 (tosedostat): Aminopeptidase inhibitor
Acute Myeloid Leukemia
Tosedostat
Acute Myeloid Leukemia
Nicotinamide riboside
Inflammation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CHR-2797 (tosedostat): Aminopeptidase inhibitor | Phase 2 | Acute Myeloid Leukemia | - | - |
Tosedostat | Phase 2 | Acute Myeloid Leukemia | - | - |
Nicotinamide riboside | Phase 2 | Inflammation | - | - |
Frequently asked questions
What is in ChromaDex Corporation's drug pipeline?β
CatalystAlert tracks 3 drug candidates in ChromaDex Corporation's (CDXC) pipeline across Phase 2. Its lead program is CHR-2797 (tosedostat): Aminopeptidase inhibitor (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ChromaDex Corporation's next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for ChromaDex Corporation (CDXC) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track CDXC biotech catalysts?β
Add CDXC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ChromaDex Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
